Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.27)
# 3,547
Out of 4,911 analysts
76
Total ratings
40.51%
Success rate
-19.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Reiterates: Overweight | n/a | $6.23 | - | 11 | Jun 26, 2025 | |
| REPL Replimune Group | Initiates: Overweight | n/a | $3.15 | - | 1 | Jun 20, 2025 | |
| ASND Ascendis Pharma | Reiterates: Overweight | $200 | $167.47 | +19.42% | 18 | May 12, 2025 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $37.17 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.43 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $3.33 | - | 1 | Mar 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $7.84 | - | 5 | Feb 7, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $0.53 | - | 7 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $24.51 | - | 2 | Jan 13, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $10.23 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $4.87 | +310.68% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.69 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.84 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.71 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.80 | +66.67% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $5.73 | +3,739.44% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.24 | +303.23% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.16 | +1,659.26% | 1 | Aug 12, 2022 |
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.23
Upside: -
Replimune Group
Jun 20, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.15
Upside: -
Ascendis Pharma
May 12, 2025
Reiterates: Overweight
Price Target: $200
Current: $167.47
Upside: +19.42%
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $37.17
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.43
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.33
Upside: -
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.84
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $0.53
Upside: -
IDEAYA Biosciences
Jan 13, 2025
Reiterates: Overweight
Price Target: n/a
Current: $24.51
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.23
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.87
Upside: +310.68%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.69
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.84
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.71
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.80
Upside: +66.67%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $5.73
Upside: +3,739.44%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.24
Upside: +303.23%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.16
Upside: +1,659.26%